Chronic Lymphocytic Leukemia

Disease State Hub

Interactive Features

Pop Quiz

Estimated Number of New Leukemia Diagnoses in 2024

02/27/2024

The American Cancer Society annually projects the number of new leukemia diagnoses in the United States. Which type of leukemia is projected to have the most diagnoses in 2024? Take the quiz to find out! ...

02/27/2024

Research Summaries

FDA Alert

FDA Alert

FDA Approves Acalabrutinib Plus Venetoclax for First-Line Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

02/20/2026

Ashton L. Stahl

The FDA has approved a chemotherapy-free combination of acalabrutinib and venetoclax for adults with previously untreated CLL or SLL, based on a randomized phase 3 trial demonstrating a progression-free...

02/20/2026

Research Summary

Research Summary

Bexobrutideg Shows Rapid, Durable Responses in Relapsed/Refractory CLL in Updated Phase 1a Trial Data

12/16/2025

Anthony Calabro, MA

Investigators evaluating the novel Bruton's Tyrosine Kinase degrader bexobrutideg (NX-5948) reported updated Phase 1a results demonstrating rapid and durable clinical responses in heavily pretreated...

12/16/2025

CONFERENCE COVERAGE

CONFERENCE COVERAGE

Real-World Outcomes Comparing Venetoclax and BTK Inhibitors Among Patients with Chronic Lymphocytic Leukemia

12/12/2025

Anthony Calabro, MA

A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...

12/12/2025

Research summary

Research summary

Can an eHealth Platform Improve Quality of Life for Patients with Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes?

11/18/2025

Anthony Calabro, MA

A randomized controlled trial evaluated the MyPal eHealth platform’s impact on quality of life among patients with chronic lymphocytic leukemia and myelodysplastic syndromes, revealing significant...

11/18/2025

Research Summary

Research Summary

Real-World Analysis Finds Higher Discontinuation and Hospitalization Rates With BTK Inhibitors vs Fixed-Duration Venetoclax in Older Adults With CLL

09/10/2025

Kate Young

Adults 66 years and older with CLL who began treatment with a Bruton’s tyrosine kinase inhibitor were more likely to discontinue early, require subsequent therapy, and experience hospitalization compared...

09/10/2025

May 2026

Current Issue

May 2026